EUVIMEDEUVIMED entdecken
Open Access

Tumor-derived RAC1 A159V mutation promotes an immunosuppressive microenvironment that represses response to immune checkpoint inhibitor

Mingjun Cai iD, Mike Adam iD, Xin Duan, Fukun Guo, Yi Zheng iD

Science Advances · 2025

DOI: 10.1126/sciadv.aea1212 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Science Advances, 2025. Verfasst von Mingjun Cai und 4 weiteren Autor:innen. Beteiligte Einrichtung: Graduate Program of Development, Stem Cells, and Regenerative Medicine, University of Cincinnati College of Medicine, 3333 Burnet Avenue, Cincinnati,…. Hauptthemen laut MEDLINE: Immune Checkpoint Inhibitors, Tumor Microenvironment, rac1 GTP-Binding Protein, Mutation. Die Arbeit nennt 80 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS, NCI NIH HHS, NIDDK NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

RAC1 A159V is a hotspot mutation associated with poor prognosis in several cancers. By gene editing, we generated endogenous homozygous and heterozygous RAC1 A159V mutations, which result in up-regulated RAC1 activity and mammalian target of rapamycin (mTOR) signaling. RAC1 A159V tumors grow faster than RAC1 WT tumors in immune-proficient mice and are resistant to anti–programmed death protein 1 (PD1). Flow cytometry and scRNA-seq analyses reveal that RAC1 A159V cells form “cold” tumors with an immunosuppressive microenvironment and reduced tumor-immune cell interactions. Mechanistically, RAC1 A159V up-regulates glycosphingolipid biosynthesis to activate mTORC1 signaling in tumor cells, which in turn increases glycolysis, impairs key chemokine production, and decreases IFNGR1 expression of the tumor cells. mTORC1 inhibition by rapamycin resensitizes the RAC1 A159V tumors to anti-PD1 treatment by reversing effects of RAC1 A159V mutation. These results demonstrate a mechanism of RAC1 A159V -driven immune evasion and suggest an approach of combining the targeting of RAC1-mTOR signaling with immune checkpoint inhibitor for the treatment of a type of immune-cold tumors.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Immune Checkpoint InhibitorsTumor Microenvironmentrac1 GTP-Binding ProteinMutationNeoplasmsNeuropeptidesAnimalsMiceHumansCell Line, TumorProgrammed Cell Death 1 ReceptorSignal TransductionMechanistic Target of Rapamycin Complex 1TOR Serine-Threonine Kinases

Substanzen

Immune Checkpoint Inhibitorsrac1 GTP-Binding ProteinProgrammed Cell Death 1 ReceptorNeuropeptidesMechanistic Target of Rapamycin Complex 1RAC1 protein, humanTOR Serine-Threonine KinasesRac1 protein, mouse

Autor:innen und Institutionen

  • Graduate Program of Development, Stem Cells, and Regenerative Medicine, University of Cincinnati College of Medicine, 3333 Burnet Avenue, Cincinnati, OH 45229, USA.
  • Division of Experimental Hematology and Cancer Biology, Cancer and Blood Diseases Institute, Children's Hospital Medical Center, and Department of Pediatrics, University of Cincinnati College of Medicine, 3333 Burnet Av…

ORCID-Profile: Mingjun Cai, Mike Adam, Yi Zheng

Förderung

  • NHLBI NIH HHS
  • NCI NIH HHS
  • NIDDK NIH HHS

Zitieren

APA

Cai, M., Adam, M., Duan, X., Guo, F., & Zheng, Y. (2025). Tumor-derived RAC1 A159V mutation promotes an immunosuppressive microenvironment that represses response to immune checkpoint inhibitor. Science Advances. https://doi.org/10.1126/sciadv.aea1212

Vancouver

Cai M, Adam M, Duan X, Guo F, Zheng Y. Tumor-derived RAC1 A159V mutation promotes an immunosuppressive microenvironment that represses response to immune checkpoint inhibitor. Science Advances. 2025. doi:10.1126/sciadv.aea1212

BibTeX
@article{Cai2025,
  author = {Cai, Mingjun and Adam, Mike and Duan, Xin and Guo, Fukun and Zheng, Yi},
  title = {Tumor-derived RAC1 A159V mutation promotes an immunosuppressive microenvironment that represses response to immune checkpoint inhibitor},
  journal = {Science Advances},
  year = {2025},
  doi = {10.1126/sciadv.aea1212}
}
Kostenlos starten →